A potent oral anticoagulant, rivaroxaban (RN), was just recently created. It was the medication that was most frequently administered during the COVID-19 epidemic. This study aims to explore the compatibility of rivaroxaban with crospovidone, sodium starch glycolate, magnesium stearate, talc, microcrystalline cellulose, aerosil, HPMC K100 M, and croscarmellose sodium using a differential scanning calorimeter and an FTIR spectrophotometer. According to DSC thermograms of rivaroxaban and a physical combination of several pharmaceutical excipients, the drug transition temperature ranged from 224°C to 232°C. The FTIR plots showed that all of the chosen pharmaceutical excipients had wave numbers that matched to rivaroxaban. The DSC and FTIR analyses revealed that RN was not interfering with the selected pharmaceutical excipients and that it may be employed in future studies. According to the investigation's findings, these combinations are safe and can be employed in future research to create rivaroxaban-containing pharmaceutical formulations.
Author (s) Details:
Rama Rao Nadendla,
Chalapathi Institute of Pharmaceutical Sciences, Chalapathi Nagar, Lam, Guntur, Andhra Pradesh, India.
J. Satynarayana,
Chalapathi Institute of Pharmaceutical Sciences, Chalapathi Nagar, Lam, Guntur, Andhra Pradesh, India.
Jaya Krishna Burri,
Chalapathi Institute of Pharmaceutical Sciences, Chalapathi Nagar, Lam, Guntur, Andhra Pradesh, India.
Please see the link here: https://stm.bookpi.org/CAPR-V4/article/view/7512
No comments:
Post a Comment